Last reviewed · How we verify

Acute myocardial infarction — Treatment Landscape & Competitive Intelligence

Acute myocardial infarction (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Acute myocardial infarction, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Tnkase TENECTEPLASE Roche fibrin 2000-01-01
Activase ALTEPLASE Roche Plasminogen 1996-01-01
Metalyse Metalyse AO GENERIUM Plasminogen
Activase Activase Medical College of Wisconsin Plasminogen

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Roche · 2 drugs in Acute myocardial infarction
  2. AO GENERIUM · 1 drug in Acute myocardial infarction
  3. Medical College of Wisconsin · 1 drug in Acute myocardial infarction

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Acute myocardial infarction:

Cite this brief

Drug Landscape (2026). Acute myocardial infarction — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acute-myocardial-infarction. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing